Furthermore, the clinical study showed that dual expression of stem cells markers, the CD133+ABCG2+ has showed early relapse in stage 1 NSCLC as compare to non-CD133+ABCG2+ (83), which will be useful target in cancer chemotherapeutic. This evidence concerns the gene ABCG2 and non-small cell lung carcinoma.